Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO5 for initially unresectable colorectal liver-only metastases
NL-OMON54605Phase 3Completed
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Oct 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, irinotecan, bevacizumab and panitumumab in colorectal cancer (CRC), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
fluorouraciloxaliplatinirinotecanbevacizumabpanitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54605.